185052-09-9
Chemical Structure
R715
- CAS No.: 185052-09-9
- Formula:C57H81N13O12
- Molecular Weight:1140.33
IUPAC Name: ((R)-2-((S)-2-((S)-2-(2-((S)-1-(acetyl-L-lysyl-L-arginyl-L-prolyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanamido)-3-(naphthalen-2-yl)propanoyl)-L-isoleucine
InChIKey: DOSXOGUJJBDRGQ-VUBDHFCFSA-N
SMILES: O=C(N1[C@@H](CCC1)C(NCC(N[C@H](C(N[C@@H](CO)C(N[C@@H](C(N[C@H](C(O)=O)[C@@H](C)CC)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)=O)CC4=CC=CC=C4)=O)=O)[C@H]5N(CCC5)C([C@H](CCCNC(N)=N)NC([C@@H](NC(C)=O)CCCCN)=O)=O
Biological Activity: R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
R715 | 99.67% | R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
